Marino Stram & Associates LLC Has $1.45 Million Holdings in Pfizer Inc. (NYSE:PFE)

Marino Stram & Associates LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,255 shares of the biopharmaceutical company’s stock after acquiring an additional 1,741 shares during the quarter. Marino Stram & Associates LLC’s holdings in Pfizer were worth $1,454,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Olistico Wealth LLC acquired a new position in Pfizer in the second quarter valued at about $25,000. MFA Wealth Advisors LLC acquired a new position in shares of Pfizer in the 2nd quarter worth approximately $29,000. Quarry LP acquired a new stake in Pfizer during the 2nd quarter valued at $31,000. Trivant Custom Portfolio Group LLC raised its position in Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares during the last quarter. Finally, Financial Connections Group Inc. acquired a new position in Pfizer in the second quarter worth $34,000. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Down 0.9 %

Shares of PFE traded down $0.27 during trading hours on Monday, reaching $28.95. The stock had a trading volume of 9,105,326 shares, compared to its average volume of 36,969,188. The company has a market cap of $164.05 billion, a P/E ratio of -483.67, a P/E/G ratio of 1.02 and a beta of 0.67. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $31.54. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The firm has a 50-day moving average of $29.07 and a 200 day moving average of $28.45.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.67 earnings per share. On average, sell-side analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.80%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio is presently -2,800.00%.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent research reports. Wells Fargo & Company increased their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Sanford C. Bernstein initiated coverage on Pfizer in a report on Thursday. They set a “market perform” rating and a $32.00 price objective for the company. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. UBS Group boosted their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Finally, Barclays raised their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.91.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.